UNSPSC 51314368: Dextromethorphan/promethazine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE507. This VA Drug Class (RE507) classifies this compound as belonging to the group ANTIHISTAMINE/ANTITUSSIVE.

UNSPSC 51314368 Dextromethorphan/promethazine (Commodity) encompasses pharmaceutical products and over-the-counter medications that state and local governments procure through competitive bidding, cooperative purchasing agreements, and market-intelligence solicitations. Recent state and local activity shows demand for generic multi-source pharmaceuticals, naloxone and drug deactivation systems for community health initiatives, and direct-to-manufacturer prescription programs. Issuing bodies include county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP). The MMCAP procurement serves multiple state and local government facilities across participating states including Oregon and Minnesota, distributing products through authorized pharmaceutical wholesalers.

The code shows activity concentrated in the Southeast and Upper Midwest, with the most recent opportunities spanning Florida, Texas, and Minnesota. Seminole County released IFB60459723LAS on June 30, 2026, seeking 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually through competitive bidding with quarterly deliveries to the Seminole County Community Health Building; the response deadline was July 26, 2023. The Minnesota Multistate Cooperative Purchasing Alliance issued RFP S1070000015802 on January 20, 2026, establishing multiple contracts for generic multi-source pharmaceuticals and OTC products across participating state and local facilities, with proposals due March 26, 2026; awards will be effective July 1, 2026. The Texas HHS Commission posted RFI HHS0017013 on April 3, 2026, gathering market intelligence on direct-to-manufacturer prescription programs to inform future procurement strategy. Cooperative purchasing vehicles and multi-award structures dominate the landscape, with vendors required to maintain specific insurance coverage, FDA compliance, and cGMP certification.